What is Clinakos?
Clinakos operates at the intersection of medical intelligence and artificial intelligence, providing a sophisticated platform for Integrated Patient Data and Medically Smart AI agents. The company specializes in addressing the complex data requirements of the pharmaceutical industry, with a specific focus on oncology and rare disease research. By offering advanced analytics and AI-driven tools, Clinakos enables life sciences organizations to optimize patient selection, streamline clinical trial outcomes, and enhance market research capabilities. With over 15 years of domain expertise, the firm serves as a critical partner for biotech companies and healthcare providers seeking to build robust, customized patient data networks and registries that drive drug development and commercialization efficiency.
How much funding has Clinakos raised?
Clinakos has raised a total of $69K across 1 funding round:
Debt
$69K
Debt (2021): $69K with participation from PPP
Key Investors in Clinakos
PPP
Public-Private Partnership
What's next for Clinakos?
With the recent infusion of capital, Clinakos is poised to scale its operational footprint and deepen its technological capabilities. The strategic focus will likely center on expanding its AI agent infrastructure to support more complex clinical development workflows and broadening its reach within the global oncology market. As the company transitions through this significant growth phase, the emphasis remains on delivering high-fidelity patient insights that reduce the time-to-market for life-saving therapies. Future initiatives will likely involve enhancing the interoperability of its data registries and strengthening its position as a leader in data-driven medical affairs.
See full Clinakos company page
